Sphere Medical has launched Proxima 4, a closed system for analysing a patient's blood gases, across the key European markets. The direct sales team will address the UK, Germany, the Netherlands and Belgium, with their distributor marketing in Italy. A new distribution partner has been announced for Spain, with launch there expected in Q217. Further regional partnerships are expected during the coming year. This represents a landmark as Sphere Medical transitions towards commercialisation. We maintain our valuation, based on our DCF-based model, at £30.2m, equivalent to 21.3p per share.
15 Dec 2016
Commercialisation now begins
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Commercialisation now begins
Sphere Medical Holding (SPHR:LON) | 0 0 0.0% | Mkt Cap: 0.037m
- Published:
15 Dec 2016 -
Author:
Franc Gregori -
Pages:
3
Sphere Medical has launched Proxima 4, a closed system for analysing a patient's blood gases, across the key European markets. The direct sales team will address the UK, Germany, the Netherlands and Belgium, with their distributor marketing in Italy. A new distribution partner has been announced for Spain, with launch there expected in Q217. Further regional partnerships are expected during the coming year. This represents a landmark as Sphere Medical transitions towards commercialisation. We maintain our valuation, based on our DCF-based model, at £30.2m, equivalent to 21.3p per share.